[HTML][HTML] Targeting autophagy for cancer treatment and tumor chemosensitization
M Pérez-Hernández, A Arias, D Martínez-García… - Cancers, 2019 - mdpi.com
… of tumors, and has already demonstrated positive clinical results in patients. In this review, …
modulation has shown controversial results in preclinical studies. For instance, it has been …
modulation has shown controversial results in preclinical studies. For instance, it has been …
Combination therapy of chemotherapy or radiotherapy and the neurokinin-1 receptor antagonist aprepitant: A new antitumor strategy?
P Robinson, R Coveñas… - Current Medicinal …, 2023 - ingentaconnect.com
… the antitumor activity (chemosensitization) of cisplatin in … In addition to the in vitro preclinical
studies, further studies to … done using patient-derived xenografts (PDX’s) in preclinical animal …
studies, further studies to … done using patient-derived xenografts (PDX’s) in preclinical animal …
Preclinical pharmacokinetics of benznidazole
P Workman, RA White, MI Walton, LN Owen… - British journal of …, 1984 - nature.com
… lipophilicity was particularly important for chemosensitization. The lipophilic analogue
benznidazole (N… These doses are similar to those used in our previous chemosensitization studies …
benznidazole (N… These doses are similar to those used in our previous chemosensitization studies …
Regulatory considerations for preclinical development of anticancer drugs
JJ DeGeorge, CH Ahn, PA Andrews, ME Brower… - Cancer chemotherapy …, 1997 - Springer
… Thus, it is important to know the plasma elimination half-life (and, if possible, tissue
elimination half-lives) in preclinical studies so that the length of time a patient should protect …
elimination half-lives) in preclinical studies so that the length of time a patient should protect …
Nitric oxide and platinum-derivative-based regimens for cancer treatment: from preclinical studies to clinical trials
S Plenchette, C Paul, A Bettaieb - … (Donor/Induced) in Chemosensitizing, 2017 - Elsevier
… patients with a wide variety of solid tumors. New effective strategies are still needed to improve
chemosensitization … Preclinical and clinical studies focused on combination therapy using …
chemosensitization … Preclinical and clinical studies focused on combination therapy using …
[HTML][HTML] Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents
… A third hypothesis, which essentially provides a mechanistic explanation for the second
hypothesis, is based on our prior preclinical observations regarding the induction of circulating …
hypothesis, is based on our prior preclinical observations regarding the induction of circulating …
Low-dose suramin enhanced paclitaxel activity in chemotherapy-naive and paclitaxel-pretreated human breast xenograft tumors
… less conventional in preclinical studies, they are used routinely in clinical drug evaluation. On
… -dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer. …
… -dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer. …
In vivo evidence of γ-tocotrienol as a chemosensitizer in the treatment of hormone-refractory prostate cancer
WN Yap, N Zaiden, SY Luk, DTW Lee, MT Ling… - Pharmacology, 2010 - karger.com
… reducing the toxicity often seen in patients treated with DTX. … promising treatment strategy
for patients with AIPCa. Finally, we … development of future preclinical and clinical studies on the …
for patients with AIPCa. Finally, we … development of future preclinical and clinical studies on the …
Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides
H Miayake, A Tolcher, ME Gleave - Journal of the National …, 2000 - academic.oup.com
… have been traditionally evaluated in patients with advanced … preclinical data provide
support for clinical studies with antisense Bcl-2 oligodeoxynucleotides plus paclitaxel for patients …
support for clinical studies with antisense Bcl-2 oligodeoxynucleotides plus paclitaxel for patients …
Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs
A Goel, BB Aggarwal - Nutrition and cancer, 2010 - Taylor & Francis
… These preclinical studies are expected to lead to clinical trials to prove the potential of this
age-old golden spice for treating cancer patients. … This review summarizes the potential role of …
age-old golden spice for treating cancer patients. … This review summarizes the potential role of …